A regimen of Roche's Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3
Merck & Co's Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche's Tecentriq in the early-stage, adjuvant trea
After three years of availability via the Cancer Drugs Fund (CDF), MSD's checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to pr
Merck & Co's strategy of pushing Keytruda earlier in the treatment pathway for cancers has secured anther victory, after the FDA approved the immunotherapy for adjuvant treatment of ski
The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priori
Merck & Co has chalked up another win in drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, after the FDA greenlit use of the drug as post-surgery (adjuv
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.